Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for chronic rhinosinusitis with nasal polyps in Chinese adults
CTR20230845Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20230845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230845.